Gland Pharma [GLAND] vs Syngene [SYNGENE] Detailed Stock Comparison
Gland Pharma
NSE
Loading...
Syngene
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gland Pharma wins in 15 metrics, Syngene wins in 5 metrics, with 0 ties. Gland Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gland Pharma | Syngene | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 40.46 | 51.54 | Gland Pharma |
| Price-to-Book Ratio | 3.41 | 5.51 | Gland Pharma |
| Debt-to-Equity Ratio | 3.43 | 12.23 | Gland Pharma |
| PEG Ratio | 0.81 | 3.61 | Gland Pharma |
| EV/EBITDA | 21.31 | 24.63 | Gland Pharma |
| Profit Margin (TTM) | 13.47% | 13.61% | Syngene |
| Operating Margin (TTM) | 17.71% | 11.44% | Gland Pharma |
| EBITDA Margin (TTM) | 17.71% | 11.44% | Gland Pharma |
| Return on Equity | 7.63% | 10.50% | Syngene |
| Return on Assets (TTM) | 6.22% | 7.30% | Syngene |
| Free Cash Flow (TTM) | $5.21B | $3.98B | Gland Pharma |
| Dividend Yield | 1.95% | 0.39% | Gland Pharma |
| 1-Year Return | -0.72% | -27.93% | Gland Pharma |
| Price-to-Sales Ratio (TTM) | 5.45 | 7.07 | Gland Pharma |
| Enterprise Value | $284.35B | $252.06B | Gland Pharma |
| EV/Revenue Ratio | 4.97 | 6.76 | Gland Pharma |
| Gross Profit Margin (TTM) | 65.39% | 75.12% | Syngene |
| Revenue per Share (TTM) | $347 | $93 | Gland Pharma |
| Earnings per Share (Diluted) | $46.77 | $12.58 | Gland Pharma |
| Beta (Stock Volatility) | 0.39 | 0.02 | Syngene |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Gland Pharma vs Syngene Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gland Pharma | 0.33% | 1.11% | -3.69% | 15.83% | 20.02% | 4.54% |
| Syngene | -1.28% | 3.59% | -7.08% | 0.26% | -4.26% | -26.26% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gland Pharma | -0.72% | -20.85% | 3.99% | 3.99% | 3.99% | 3.99% |
| Syngene | -27.93% | 13.39% | 36.52% | 293.57% | 305.20% | 305.20% |
Performance & Financial Health Analysis: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹311.82B | ₹260.75B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 94,738 | 630,328 |
| 90 Day Avg. Volume | 247,738 | 870,234 |
| Last Close | ₹1,892.20 | ₹648.40 |
| 52 Week Range | ₹1,277.80 - ₹2,131.00 | ₹599.55 - ₹960.60 |
| % from 52W High | -11.21% | -32.50% |
| All-Time High | ₹4,350.00 (Aug 09, 2021) | ₹960.60 (Dec 02, 2024) |
| % from All-Time High | -56.50% | -32.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.11% |
| Quarterly Earnings Growth | 0.50% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.14% |
| Operating Margin (TTM) | 0.18% | 0.11% |
| Return on Equity (TTM) | 0.08% | 0.11% |
| Debt to Equity (MRQ) | 3.43 | 12.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹555.41 | ₹117.59 |
| Cash per Share (MRQ) | ₹179.19 | ₹34.82 |
| Operating Cash Flow (TTM) | ₹7.50B | ₹5.00B |
| Levered Free Cash Flow (TTM) | ₹6.99B | ₹4.96B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.95% | 0.39% |
| Last 12-Month Dividend | ₹38.00 | ₹2.50 |
Valuation & Enterprise Metrics Analysis: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 40.46 | 51.54 |
| Forward P/E | 29.11 | 38.48 |
| PEG Ratio | 0.81 | 3.61 |
| Price to Sales (TTM) | 5.45 | 7.07 |
| Price to Book (MRQ) | 3.41 | 5.51 |
| Market Capitalization | ||
| Market Capitalization | ₹311.82B | ₹260.75B |
| Enterprise Value | ₹284.35B | ₹252.06B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.97 | 6.76 |
| Enterprise to EBITDA | 21.31 | 24.63 |
| Risk & Other Metrics | ||
| Beta | 0.39 | 0.02 |
| Book Value per Share (MRQ) | ₹555.41 | ₹117.59 |
Financial Statements Comparison: Gland Pharma vs Syngene
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Revenue/Sales | ₹15.06B | ₹8.75B |
| Cost of Goods Sold | ₹5.21B | ₹2.18B |
| Gross Profit | ₹9.84B | ₹6.57B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.67B | ₹1.00B |
| EBITDA | ₹4.25B | ₹2.24B |
| Pre-Tax Income | ₹3.13B | ₹1.01B |
| Income Tax | ₹972.59M | ₹146.00M |
| Net Income (Profit) | ₹2.15B | ₹867.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Cash & Equivalents | ₹25.56B | ₹3.67B |
| Total Current Assets | ₹67.83B | ₹22.87B |
| Total Current Liabilities | ₹15.65B | ₹13.96B |
| Long-Term Debt | ₹1.07B | ₹4.09B |
| Total Shareholders Equity | ₹91.51B | ₹47.27B |
| Retained Earnings | ₹71.57B | ₹38.82B |
| Property, Plant & Equipment | ₹3.59B | ₹27.42B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Operating Cash Flow | ₹2.07B | ₹2.17B |
| Capital Expenditures | ₹-659.37M | ₹-680.00M |
| Free Cash Flow | ₹126.04M | ₹1.27B |
| Debt Repayment | N/A | ₹0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLAND | SYNGENE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 94,738 | 630,328 |
| Average Daily Volume (90 Day) | 247,738 | 870,234 |
| Shares Outstanding | 164.76M | 401.37M |
| Float Shares | 73.18M | 175.53M |
| % Held by Insiders | 0.52% | 0.53% |
| % Held by Institutions | 0.37% | 0.32% |
Dividend Analysis & Yield Comparison: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Last 12-Month Dividend | ₹38.00 | ₹2.50 |
| Last 12-Month Dividend Yield | 1.95% | 0.39% |
| 3-Year Avg Annual Dividend | ₹12.67 | ₹1.25 |
| 3-Year Avg Dividend Yield | 1.00% | 0.14% |
| 3-Year Total Dividends | ₹38.00 | ₹3.75 |
| Ex-Dividend Date | Aug 14, 2025 | Jun 27, 2025 |